168 related articles for article (PubMed ID: 17767744)
1. Therapeutic targets in systemic sclerosis.
Denton CP
Arthritis Res Ther; 2007; 9 Suppl 2(Suppl 2):S6. PubMed ID: 17767744
[TBL] [Abstract][Full Text] [Related]
2. Targeted therapy comes of age in scleroderma.
Denton CP; Black CM
Trends Immunol; 2005 Nov; 26(11):596-602. PubMed ID: 16168710
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms and consequences of fibrosis in systemic sclerosis.
Denton CP; Black CM; Abraham DJ
Nat Clin Pract Rheumatol; 2006 Mar; 2(3):134-44. PubMed ID: 16932673
[TBL] [Abstract][Full Text] [Related]
4. Endothelin receptor selectivity: evidence from in vitro and pre-clinical models of scleroderma.
Shiwen X; Leask A; Abraham DJ; Fonseca C
Eur J Clin Invest; 2009 Jun; 39 Suppl 2():19-26. PubMed ID: 19335743
[TBL] [Abstract][Full Text] [Related]
5. The immunobiology of systemic sclerosis.
Gu YS; Kong J; Cheema GS; Keen CL; Wick G; Gershwin ME
Semin Arthritis Rheum; 2008 Oct; 38(2):132-60. PubMed ID: 18221988
[TBL] [Abstract][Full Text] [Related]
6. Future targets in the management of systemic sclerosis.
Tyndall A; Matucci-Cerinic M; Müller-Ladner U
Rheumatology (Oxford); 2009 Jun; 48 Suppl 3():iii49-53. PubMed ID: 19487225
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic challenges for systemic sclerosis: facts and future targets.
Cerinic Matucci M; Del Rosso A; Federico P; Livi R; Fiori G; Bartoli F; Blagojevic J; Tempestini A; Pignone A
Ann N Y Acad Sci; 2007 Sep; 1110():448-54. PubMed ID: 17911460
[TBL] [Abstract][Full Text] [Related]
8. How does endothelial cell injury start? The role of endothelin in systemic sclerosis.
Abraham D; Distler O
Arthritis Res Ther; 2007; 9 Suppl 2(Suppl 2):S2. PubMed ID: 17767740
[TBL] [Abstract][Full Text] [Related]
9. Molecular pathways as novel therapeutic targets in systemic sclerosis.
Trojanowska M; Varga J
Curr Opin Rheumatol; 2007 Nov; 19(6):568-73. PubMed ID: 17917537
[TBL] [Abstract][Full Text] [Related]
10. Overview of pathogenesis of systemic sclerosis.
Abraham DJ; Krieg T; Distler J; Distler O
Rheumatology (Oxford); 2009 Jun; 48 Suppl 3():iii3-7. PubMed ID: 19487220
[TBL] [Abstract][Full Text] [Related]
11. Connective tissue growth factor: growth factor, matricellular organizer, fibrotic biomarker or molecular target for anti-fibrotic therapy in SSc?
Abraham D
Rheumatology (Oxford); 2008 Oct; 47 Suppl 5():v8-9. PubMed ID: 18784153
[TBL] [Abstract][Full Text] [Related]
12. Clinical burden of digital vasculopathy in limited and diffuse cutaneous systemic sclerosis.
Nihtyanova SI; Brough GM; Black CM; Denton CP
Ann Rheum Dis; 2008 Jan; 67(1):120-3. PubMed ID: 17660220
[TBL] [Abstract][Full Text] [Related]
13. [Lung impairment in systemic sclerosis].
Knoop H; Arinir U; Kreuter A; Walther JW; Schultze-Werninghaus G; Rohde G
Pneumologie; 2009 Sep; 63(9):497-507. PubMed ID: 19708006
[TBL] [Abstract][Full Text] [Related]
14. Pathogenesis and therapeutic approaches for improved topical treatment in localized scleroderma and systemic sclerosis.
Badea I; Taylor M; Rosenberg A; Foldvari M
Rheumatology (Oxford); 2009 Mar; 48(3):213-21. PubMed ID: 19022832
[TBL] [Abstract][Full Text] [Related]
15. Systemic sclerosis/scleroderma: a treatable multisystem disease.
Hinchcliff M; Varga J
Am Fam Physician; 2008 Oct; 78(8):961-8. PubMed ID: 18953973
[TBL] [Abstract][Full Text] [Related]
16. [Pathogenic mechanisms in systemic sclerosis and their therapeutical consequences. Part 2: treatment].
Zuber JP; Chizzolini C; Leimgruber A; Bart PA; Spertini F
Rev Med Suisse; 2006 Apr; 2(62):1058, 1060-6. PubMed ID: 16711151
[TBL] [Abstract][Full Text] [Related]
17. [Systemic sclerosis--pathogenesis, clinical manifestations and treatment].
Radić M; Kaliterna DM; Fabijanić D; Radić J
Lijec Vjesn; 2010; 132(5-6):162-8. PubMed ID: 20677623
[TBL] [Abstract][Full Text] [Related]
18. Systemic sclerosis: an update.
Varga J
Bull NYU Hosp Jt Dis; 2008; 66(3):198-202. PubMed ID: 18937632
[TBL] [Abstract][Full Text] [Related]
19. Effector CD8+ T cells in systemic sclerosis patients produce abnormally high levels of interleukin-13 associated with increased skin fibrosis.
Fuschiotti P; Medsger TA; Morel PA
Arthritis Rheum; 2009 Apr; 60(4):1119-28. PubMed ID: 19333920
[TBL] [Abstract][Full Text] [Related]
20. Scleroderma: from pathophysiology to novel therapeutic approaches.
Hunzelmann N; Krieg T
Exp Dermatol; 2010 May; 19(5):393-400. PubMed ID: 20507361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
